Programmed Death (PD)-1 Non-Small Cell Lung Cancer Global Market Report 2025
상품코드:1811013
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계의 PD-1 비소세포폐암 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년까지 CAGR 8.6%로 확대되어 382억 6,000만 달러로 성장할 것으로 예상됩니다. 예측기간 중 성장은 암 전용 인프라에 대한 투자 증가, 신흥 시장에서 생물제제에 대한 환자 접근 확대, 세계적인 노인 증가, 면역요법에 대한 상환 지원 강화, PD-1 억제제의 임상 성공률 상승 등에 기인할 것으로 예측됩니다. 이 기간에 예상되는 주요 동향으로는 바이오마커 검사의 기술적 진보, 병용 면역요법 프로토콜의 진보, 맞춤형 치료 전략에 대한 투자, 신규 PD-1 억제제의 연구개발의 진행, 면역 체크포인트 저해 메커니즘의 혁신 등을 들 수 있습니다.
맞춤형 치료의 채용 확대가 PD-1 비소세포 폐암 시장의 성장을 견인할 것으로 예측됩니다. 개인화 치료에는 개인의 유전적 체질, 라이프 스타일 및 특정 질병 특성에 맞게 맞춤형 의료 접근법이 포함되어 더욱 효과적인 결과를 얻을 수 있습니다. 개인화 치료에 대한 수요 증가는 특정 돌연변이 및 생물학적 마커를 확인하는 데 도움이 되는 유전체 프로파일링 및 바이오마커 검사를 널리 이용할 수 있게 되었습니다. 맞춤형 치료는 환자의 유전자 프로파일, 종양 특징, 면역 반응에 따라 치료법을 조정하여 PD-1 비소세포폐암(NSCLC)의 치료를 지원합니다. 예를 들어, 2024년 2월 미국을 기반으로 하는 비영리 단체인 맞춤형 의료연합(Personalized Medicine Coalition)은 미국 식품의약국(FDA)이 희소질환에 대한 새로운 맞춤형 치료를 2022년 6건에 대해 2023년에는 16건 승인했다고 보고했습니다. 이와 같이 맞춤형 치료의 보급이 PD-1 비소세포폐암 시장의 확대에 기여하고 있습니다.
PD-1 비소세포폐암 시장의 주요 기업은 환자의 예후를 개선하기 위해 단일 요법과 같은 혁신적인 치료법의 임상 검사를 실시했습니다. 단일 요법이란 질병과 병태를 다루기 위해 단일 약물과 치료법을 사용하는 치료 전략을 말합니다. 예를 들어, 2025년 3월 중국에 본사를 둔 바이오의약품 기업 Akeso, Inc.는 진행 비소세포폐암(NSCLC)의 1차 치료로서 화학요법과 병용하는 Ivonescimab(AK112)을 평가하는 3상 HARMONi-2 검사의 양호한 결과를 발표했습니다. 본 검사에서는 펨브롤리주맙에 비해 무증상 생존기간을 유의하게 연장함으로써 주요 평가항목을 달성하여 이 이중 표적 이중 특이성 항체의 치료가능성을 나타냈습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 PD-1 비소세포폐암 시장 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 PD-1 비소세포폐암 시장 : 성장률 분석
세계의 PD-1 비소세포폐암 시장 실적: 규모와 성장, 2019-2024년
세계의 PD-1 비소세포폐암 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 PD-1 비소세포폐암 시장 : 총 시장 규모(TAM)
제6장 시장 세분화
세계의 PD-1 비소세포폐암 시장 : 약제 유형별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
단제 요법
병용 요법
세계의 PD-1 비소세포폐암 시장 : 치료 부문별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
제1선택 치료
제2선택 및 이후
세계의 PD-1 비소세포폐암 시장 : 최종 사용자별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
병원
전문 암 센터
학술연구기관
기타
세계의 PD-1 비소세포폐암 시장 : 단제 요법별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
펜브롤리주맙(Keytruda)
니볼루마브(Opdivo)
세미프리맙(Libtayo)
트리팔리맙
티슬레리주맙
캠렐리주맙
도스탈리맙
기타
세계의 PD-1 비소세포폐암 시장 : 병용 요법별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
PD-1 억제제 및 화학요법
PD-1 억제제 및 세포독성 T 림프구 관련 단백질(CTLA)-4 억제제
PD-1 억제제 및 혈관 내피 증식 인자(VEGF) 억제제
PD-1 억제제 및 표적 요법
PD-1 억제제 및 방사선 요법
트리플 콤비네이션 요법
PD-1 억제제 및 메신저 리보 핵산(mRNA) 백신
기타
제7장 지역별/국가별 분석
세계의 PD-1 비소세포폐암 시장 : 지역별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 PD-1 비소세포폐암 시장 : 국가별, 분석과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
PD-1 비소세포폐암 시장 : 경쟁 구도
PD-1 비소세포폐암 시장 : 기업 프로파일
F. Hoffmann-La Roche Ltd
Merck & Co. Inc.
AbbVie Inc.
Sanofi SA
Novartis AG
제31장 기타 주요 기업 및 혁신 기업
GlaxoSmithKline plc
Regeneron Pharmaceuticals Inc.
Incyte Corporation
Ono Pharmaceutical Co. Ltd.
BeiGene Ltd.
BioNTech SE
Shanghai Junshi Biosciences Co. Ltd.
MacroGenics Inc.
Akeso Inc.
Arcus Biosciences Inc.
Shandong Boan BIoTechnology Co. Ltd.
CStone Pharmaceuticals
iTeos Therapeutics Inc.
Summit Therapeutics Inc.
Shanghai Henlius BIoTech Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 전략
PD-1 비소세포폐암 시장(2029년) : 새로운 기회를 제공하는 국가
PD-1 비소세포폐암 시장(2029년) : 새로운 기회를 제공하는 부문
PD-1 비소세포폐암 시장(2029년) : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제36장 부록
JHS
영문 목차
영문목차
Programmed death-1 (PD-1) non-small cell lung cancer (NSCLC) is a type of lung cancer in which the tumor avoids immune system detection by utilizing the PD-1 pathway, an important immune checkpoint. PD-1 is a receptor found on T cells that, when bound by its ligands (PD-L1 or PD-L2), dampens immune responses to protect tissues from damage. In NSCLC, tumors frequently overexpress PD-L1, allowing them to evade the immune system and promote cancer growth.
The main categories in the programmed death (PD)-1 non-small cell lung cancer market include monotherapy and combination therapy. Monotherapy involves treating the disease with a single drug, without combining it with other treatments. It is applied across various therapy lines, including first-line, second-line, and later stages, and is used by diverse end users such as hospitals, specialized cancer centers, academic and research institutions, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The programmed death (PD)-1 non-small cell lung cancer market research report is one of a series of new reports from The Business Research Company that provides programmed death (PD)-1 non-small cell lung cancer market statistics, including programmed death (PD)-1 non-small cell lung cancer industry global market size, regional shares, competitors with a programmed death (PD)-1 non-small cell lung cancer market share, detailed programmed death (PD)-1 non-small cell lung cancer market segments, market trends and opportunities, and any further data you may need to thrive in the programmed death (PD)-1 non-small cell lung cancer industry. This programmed death (PD)-1 non-small cell lung cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The programmed death (PD)-1 non-small cell lung cancer market size has grown strongly in recent years. It will grow from $25.23 billion in 2024 to $27.50 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth during the historical period can be attributed to the rising prevalence of non-small cell lung cancer, increased adoption of immunotherapy in developed countries, greater awareness of cancer screening, more approvals for monoclonal antibodies, and higher healthcare spending.
The programmed death (PD)-1 non-small cell lung cancer market size is expected to see strong growth in the next few years. It will grow to $38.26 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The projected growth in the forecast period can be attributed to increasing investments in cancer-specific infrastructure, expanding patient access to biologics in emerging markets, a growing global geriatric population, enhanced reimbursement support for immunotherapies, and rising clinical success rates of PD-1 inhibitors. Key trends expected during this period include technological advancements in biomarker testing, progress in combination immunotherapy protocols, investments in personalized treatment strategies, ongoing research and development of novel PD-1 inhibitors, and innovations in immune checkpoint blockade mechanisms.
The growing adoption of personalized treatments is expected to drive growth in the programmed death (PD)-1 non-small cell lung cancer market. Personalized treatments involve medical approaches customized to an individual's genetic makeup, lifestyle, and specific disease traits to achieve more targeted and effective results. The increased demand for personalized therapies is fueled by the wider availability of genomic profiling and biomarker testing, which help identify particular mutations and biological markers, enabling clinicians to select treatments likely to be more effective for each patient. Personalized treatments assist programmed death (PD)-1 non-small cell lung cancer (NSCLC) care by tailoring therapies according to a patient's genetic profile, tumor features, and immune response. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based non-profit organization, reported that the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases in 2023, compared to six in 2022. Thus, the increasing use of personalized treatments is contributing to the expansion of the PD-1 non-small cell lung cancer market.
Key companies in the programmed death (PD)-1 non-small cell lung cancer market are conducting clinical trials on innovative therapies, such as monotherapy, to enhance patient outcomes. Monotherapy refers to a treatment strategy that employs a single drug or therapy to address a disease or condition. For instance, in March 2025, Akeso, Inc., a China-based biopharmaceutical firm, announced positive Phase III HARMONi-2 trial results evaluating Ivonescimab (AK112) combined with chemotherapy as a first-line treatment for advanced non-small cell lung cancer (NSCLC). The trial achieved its primary endpoint by significantly prolonging progression-free survival compared to pembrolizumab, showcasing the therapeutic potential of this dual-targeted bispecific antibody.
In February 2025, BioNTech SE, a Germany-based biotechnology company, acquired Biotheus Inc. for an undisclosed sum. This acquisition provided BioNTech access to Biotheus's lead candidate, PM8002, a bispecific antibody targeting PD-L1 and vascular endothelial growth factor (VEGF)-A, which is in late-stage clinical trials for non-small cell lung cancer and other solid tumors. Biotheus Inc. is a China-based company specializing in the development of multispecific biologics and immuno-oncology therapies for cancer treatment, including PD-1 therapies for NSCLC.
Major players in the programmed death (pd)-1 non-small cell lung cancer market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Incyte Corporation, Ono Pharmaceutical Co. Ltd., BeiGene Ltd., BioNTech SE, Shanghai Junshi Biosciences Co. Ltd., MacroGenics Inc., Akeso Inc., Arcus Biosciences Inc., Shandong Boan Biotechnology Co. Ltd., CStone Pharmaceuticals, iTeos Therapeutics Inc., Summit Therapeutics Inc., and Shanghai Henlius Biotech Inc.
North America was the largest region in the programmed death (PD)-1 non-small cell lung cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in programmed death-1 (PD-1) non-small cell lung cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the programmed death-1 (PD-1) non-small cell lung cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The programmed death-1 (PD-1) non-small cell lung cancer market consists of revenues earned by entities by providing services such as clinical oncology services for immunotherapy administration, companion diagnostic testing, and comprehensive patient support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The programmed death-1 (PD-1) non-small cell lung cancer market also includes sales of pembrolizumab (Keytruda), nivolumab (Opdivo), and cemiplimab (Libtayo). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Programmed Death (PD)-1 Non-Small Cell Lung Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on programmed death (pd)-1 non-small cell lung cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for programmed death (pd)-1 non-small cell lung cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The programmed death (pd)-1 non-small cell lung cancer market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Type: Monotherapy; Combination Therapy
2) By Line of Therapy: First-line Treatment; Second-line And Beyond
3) By End User: Hospitals; Specialty Cancer Centers; Academic And Research Institutes; Other End Users
Subsegments:
1) By Monotherapy: Pembrolizumab (Keytruda); Nivolumab (Opdivo); Cemiplimab (Libtayo); Toripalimab; Tislelizumab; Camrelizumab; Dostarlimab; Other Monotherapy Drug Types
2) By Combination Therapy: Programmed Death (PD)-1 Inhibitor And Chemotherapy; Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor; Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor; Programmed Death (PD)-1 Inhibitor And Targeted Therapy; Programmed Death (PD)-1 Inhibitor And Radiation Therapy; Triple Combination Therapy; Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine; Other Combination Drug Types
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Characteristics
3. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Trends And Strategies
4. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Growth Analysis And Strategic Analysis Framework
5.1. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Growth Rate Analysis
5.4. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Total Addressable Market (TAM)
6. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Segmentation
6.1. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monotherapy
Combination Therapy
6.2. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
First-line Treatment
Second-line And Beyond
6.3. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Cancer Centers
Academic And Research Institutes
Other End Users
6.4. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Sub-Segmentation Of Monotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pembrolizumab (Keytruda)
Nivolumab (Opdivo)
Cemiplimab (Libtayo)
Toripalimab
Tislelizumab
Camrelizumab
Dostarlimab
Other Monotherapy Drug Types
6.5. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Sub-Segmentation Of Combination Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Programmed Death (PD)-1 Inhibitor And Chemotherapy
Programmed Death (PD)-1 Inhibitor And Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 Inhibitor
Programmed Death (PD)-1 Inhibitor And Vascular Endothelial Growth Factor (VEGF) Inhibitor
Programmed Death (PD)-1 Inhibitor And Targeted Therapy
Programmed Death (PD)-1 Inhibitor And Radiation Therapy
Triple Combination Therapy
Programmed Death (PD)-1 Inhibitor And Messenger Ribonucleic Acid (mRNA) Vaccine
Other Combination Drug Types
7. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Regional And Country Analysis
7.1. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
8.1. Asia-Pacific Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
9.1. China Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
9.2. China Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
10.1. India Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
11.1. Japan Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
11.2. Japan Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
12.1. Australia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
13.1. Indonesia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
14.1. South Korea Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
14.2. South Korea Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
15.1. Western Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
15.2. Western Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
16.1. UK Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
17.1. Germany Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
18.1. France Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
19.1. Italy Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
20.1. Spain Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
21.1. Eastern Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
21.2. Eastern Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
22.1. Russia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
23.1. North America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
23.2. North America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
24.1. USA Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
24.2. USA Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
25.1. Canada Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
25.2. Canada Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
26.1. South America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
26.2. South America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
27.1. Brazil Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
28.1. Middle East Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
28.2. Middle East Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
29.1. Africa Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Overview
29.2. Africa Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By Line of Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Competitive Landscape And Company Profiles
30.1. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Competitive Landscape
30.2. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Company Profiles
30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
31. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Other Major And Innovative Companies
31.1. GlaxoSmithKline plc
31.2. Regeneron Pharmaceuticals Inc.
31.3. Incyte Corporation
31.4. Ono Pharmaceutical Co. Ltd.
31.5. BeiGene Ltd.
31.6. BioNTech SE
31.7. Shanghai Junshi Biosciences Co. Ltd.
31.8. MacroGenics Inc.
31.9. Akeso Inc.
31.10. Arcus Biosciences Inc.
31.11. Shandong Boan Biotechnology Co. Ltd.
31.12. CStone Pharmaceuticals
31.13. iTeos Therapeutics Inc.
31.14. Summit Therapeutics Inc.
31.15. Shanghai Henlius Biotech Inc.
32. Global Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
34. Recent Developments In The Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market
35. Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market High Potential Countries, Segments and Strategies
35.1 Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market In 2029 - Countries Offering Most New Opportunities
35.2 Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market In 2029 - Segments Offering Most New Opportunities
35.3 Programmed Death (PD)-1 Non-Small Cell Lung Cancer Market In 2029 - Growth Strategies
